European Biopharma Therapeutics (EBT) is a specialty pharmaceuticals platform founded in 2022 by Dr. Andreas Penk and Dr. Thomas Rudolph. With the involvement of nine additional professionals boasting a combined 200+ years of experience in large and medium-sized pharma, EBT emerged as a novel player in the field.
What sets EBT apart is its unique hybrid quality—combining leaders experienced in “Big Pharma” with a track record of successful outcomes and high-quality behavior, along with a “digital first” operating model. Leveraging the latest technological approaches and experienced tech talent, EBT aims to revolutionize the way pharmaceuticals are developed and delivered.
Through years of product launches and establishment of pharmaceutical entities, EBT has developed an in-depth familiarity with the market. They boast a unique network of European oncologists, global Key Opinion Leaders (KOLs), and access to industry-leading knowledge and processes. This enables them to identify appropriate patients and ensure the delivery of precision medicine through physicians and hospitals.
EBT’s unique structure and business model aim to provide innovative and effective solutions in oncology. Their combination of vast experience and a digital-first approach supports their vision of delivering the best service to patients and pioneering advancements in precision medicine.
European Biopharma Therapeutics continues to grow and make an impact in the field of oncology, striving to enhance the quality of life for patients in the years to come.
